Two Big Pharma firms are taking a novel approach with their upcoming blockbuster drugs: pricing them below the competition. Drugmakers have taken heat recently for setting exorbitant sticker prices—and while these latest efforts are a step in the right direction, there’s still a long way to go to curb health care overspending.
© 2025 Hedgeye Risk Management, LLC ·
Substack is the home for great culture